(0)

DIA会员及用户请点击登录

登录

忘记用户 ID？ or 忘记密码？

Not a Member?

创建账户并加入。

Bethesda North Marriott Hotel and Conference Center

2017 年 10 月 25 日 7:00 上午 - 2017 年 10 月 27 日 3:00 下午

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

返回 Agenda

Session 1: The Emerging Landscape of mRNA-Based Drugs: A New Modality in Vaccines and Therapeutics

Session Chair(s)

Tal Zaks, MD, PHD

Tal Zaks, MD, PHD

Venture Partner, OrbiMed, United States

mRNA therapeutics are unique, relative to most oligonucleotide-based modalities like antisense, siRNAs, and aptapers in that mRNAs enable expression of the encoded protein rather than act as antagonists to inhibit target protein translation or activity. Early clinical data indicate that mRNA-based drugs may be effective vaccines and their potential as therapeutics is now emerging. This session will describe the general approach to mRNA manufacture, present emerging preclinical and clinical data on mRNA vaccines and therapeutics, and provide a regulatory perspective on the product-related (CMC) aspects of mRNA drug development.

Learning Objective :
  • Analyze the general approach to CMC regulation of mRNA drugs and differentiate relative to synthetic oligonucleotides
  • Describe the current development status of mRNA vaccines and therapeutics

    • Speaker(s)

    Ramachandra G Naik, MD

    Ramachandra G Naik, MD

    Primary Reviewer, Regulatory Project Manager, OVRR, CBER, FDA, United States

    Session Co-Chair

    Tal Zaks, MD, PHD

    Tal Zaks, MD, PHD

    Venture Partner, OrbiMed, United States

    Translating mRNA Vaccines and Therapeutics: First Clinical Steps

    Sarah Beach Voytek

    Sarah Beach Voytek

    Principal Scientist , Novartis Institutes For Biomedical Research, Inc., United States

    Considerations for the Nonclinical Development of Systemically-Administered Therapeutic mRNA

    Ulrike Gnad-Vogt, MD

    Ulrike Gnad-Vogt, MD

    Chief Medical Officer, Curevac, Germany

    Clinical Development of mRNA Vaccines and Immunotherapies: Experiences and Lessons Learned

    Keith Peden, PHD

    Keith Peden, PHD

    Laboratory Chief, Laboratory of DNA Viruses, DVP, CBER, FDA, United States

    Regulatory Perspective on the Product-Related (CMC) Aspects of mRNA Vaccines

    Panel Discussion

    Panel Discussion

    , All Session Speakers, United States

    获得信息并保持参与

    不要错失任何机会——请加入我们的邮件列表，了解DIA的观点和事件。